Tag: Therapy & Procedures: Misc.
Convalescent Plasma Appears Promising for Severe COVID-19
In series of 25 patients, 19 experienced improvement in clinical status by day 14; 11 were discharged
Pulmonary Rehab Associated With Lower COPD Mortality
Only 1.5 percent of patients initiated pulmonary rehabilitation within 90 days of discharge
SGLT2 Inhibitors Linked to Reduced Risk for Serious Renal Events
Data from three countries showed drop in serious renal events with sodium-glucose cotransporter 2 inhibitors
NT-proBNP Does Not Improve Evaluation of Syncope in the ED
Serum NT-proBNP concentrations were generally higher in patients with 30-day serious adverse events
PFS Prolonged With Continuous Dabrafenib, Trametinib in Melanoma
Median PFS longer with continuous versus intermittent treatment, but overall survival similar
USPSTF: Behavioral Interventions Likely Prevent Tobacco Use
Primary care-feasible behavioral interventions have moderate net benefit for school-aged children
Adding High-Dose Chloroquine Not Advised for Severe COVID-19
High-dose versus low-dose group had higher lethality until day 13, more instances of QTc interval >500 ms
Expert Panel: There Are No Proven Drug Treatments for COVID-19
Whenever possible, drugs should be given to COVID-19 patients as part of a clinical trial
Physicians Report Expanding Use of Off-Label COVID-19 Treatments
Hydroxychloroquine usage increasing rapidly, although plasma from recovered patients perceived as more effective
Convalescent Plasma Treatment Promising in Severe COVID-19
One dose of CP with neutralizing antibodies can reduce viral load, tends to improve clinical symptoms
